Alzheimer’s drug rejected for widespread NHS use in England
Health spending watchdog says donanemab ‘does not currently demonstrate value for the NHS’A new Alzheimer’s drug has been rejected for widespread use by the NHS in England after the health spending watchdog...
Read More